Skip to main content
Erschienen in: Clinical Rheumatology 10/2007

01.10.2007 | Original Article

Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study

verfasst von: Shuang Ye, Xiao-xiang Chen, Xiao-ye Lu, Mei-fang Wu, Yun Deng, Wen-qun Huang, Qiang Guo, Cheng-de Yang, Yue-ying Gu, Chun-de Bao, Shun-le Chen

Erschienen in: Clinical Rheumatology | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to investigate the characteristics of adult clinically amyopathic dermatomyositis (CADM) with rapid progressive interstitial lung disease (ILD). Hospitalized patients with dermatomyositis (DM) and polymyositis (PM) between 1998 and 2005 in the Shanghai Renji Hospital were retrospectively studied. One hundred and forty-five patients were classified into CADM, classic DM or PM according to the modified Sontheimer’s definition or Bohan–Peter’s classification criteria. They were further stratified based on the presence or absence of clinical ILD. The Kaplan–Meier survival analysis and COX regression were performed. The predictive factors for ILD and other clinical properties of CADM-ILD were explored. The presence of clinical ILD was a significant risk factor for the poor outcome of DM/PM (OR = 4.237, CI 95%: 1.239–14.49, p = 0.021). Other risk factors are the presence of rashes and elevated urea nitrogen. Patients with DM/PM complicated by ILD had different clinical courses. Patients with CADM-ILD showed a rapidly progressive pattern with 6-month survival rate of 40.8%. The DM-ILD manifested a progressive pattern with a 5-year survival rate of 54%, while PM-ILD was chronic with 5- and 10-year survival rate of 72.4% and 60.3%, respectively. Better preserved muscle strength, elevated erythrocyte sedimentation rate, and hypoalbuminemia may herald ILD in DM/PM. Patients with CADM-ILD who later died had lower PO2, higher lactate dehydrogenase, and prominent arthritis/arthralgia compared with those who survived. The presence of antinuclear antibody seems to be protective. Rapid progressive CADM-ILD is refractory to conventional treatment. ILD is a common complication in over 40% of our hospitalized DM/PM cohort and is also a prominent prognostic indicator. CADM is a special phenotype of DM/PM. CADM-ILD, which is usually rapidly progressive and fatal, requires further investigation.
Literatur
1.
Zurück zum Zitat Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706PubMedCrossRef Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706PubMedCrossRef
2.
Zurück zum Zitat Takizawa H, Suzuki N, Yanagawa T et al (1996) Outcome in patients with interstitial lung disease and polymyositis–dermatomyositis. A subgroup of poor prognosis. Japanese Journal of Thoracic Diseases 34:1093–1097 Takizawa H, Suzuki N, Yanagawa T et al (1996) Outcome in patients with interstitial lung disease and polymyositis–dermatomyositis. A subgroup of poor prognosis. Japanese Journal of Thoracic Diseases 34:1093–1097
3.
Zurück zum Zitat Ito M, Kaise S, Suzuki S et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18:462–467PubMedCrossRef Ito M, Kaise S, Suzuki S et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18:462–467PubMedCrossRef
4.
Zurück zum Zitat Lee CS, Chen TL, Tzen CY et al (2002) Idiopathic inflammatory myositis with diffuse alveolar damage. Clin Rheumatol 21:391–396PubMedCrossRef Lee CS, Chen TL, Tzen CY et al (2002) Idiopathic inflammatory myositis with diffuse alveolar damage. Clin Rheumatol 21:391–396PubMedCrossRef
5.
Zurück zum Zitat Sontheimer RD, Miyagawa S (2003) Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. J Am Acad Dermatol 48:797–798PubMedCrossRef Sontheimer RD, Miyagawa S (2003) Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. J Am Acad Dermatol 48:797–798PubMedCrossRef
6.
Zurück zum Zitat Kang EH, Lee EB, Shin KC et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44:1282–1286CrossRef Kang EH, Lee EB, Shin KC et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44:1282–1286CrossRef
7.
Zurück zum Zitat Neuhaus IM, Connolly MK (2006) An unusual presentation of amyopathic dermatomyositis associated with fatal interstitial lung disease. Arch Dermatol 142:113–114PubMedCrossRef Neuhaus IM, Connolly MK (2006) An unusual presentation of amyopathic dermatomyositis associated with fatal interstitial lung disease. Arch Dermatol 142:113–114PubMedCrossRef
8.
Zurück zum Zitat Sontheimer RD (1999) Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 11:475–482PubMedCrossRef Sontheimer RD (1999) Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 11:475–482PubMedCrossRef
9.
Zurück zum Zitat Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636PubMedCrossRef Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636PubMedCrossRef
10.
Zurück zum Zitat Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56:255–286PubMedCrossRef Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56:255–286PubMedCrossRef
11.
Zurück zum Zitat Santiago MB, Chalhoub M, Pereira ST (1998) Amyopathic dermatomyositis complicated by interstitial pulmonary disease and pneumomediastinum. J Rheumatol 25:2042–2043PubMed Santiago MB, Chalhoub M, Pereira ST (1998) Amyopathic dermatomyositis complicated by interstitial pulmonary disease and pneumomediastinum. J Rheumatol 25:2042–2043PubMed
12.
Zurück zum Zitat Yamanishi Y, Maeda H, Konishi F et al (1999) Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. Scand J Rheumatol 28:58–61PubMedCrossRef Yamanishi Y, Maeda H, Konishi F et al (1999) Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. Scand J Rheumatol 28:58–61PubMedCrossRef
13.
Zurück zum Zitat Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine’ myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597–613PubMedCrossRef Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine’ myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597–613PubMedCrossRef
14.
Zurück zum Zitat el-Azhary RA, Pakzad SY (2002) Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 46:560–565PubMedCrossRef el-Azhary RA, Pakzad SY (2002) Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 46:560–565PubMedCrossRef
15.
Zurück zum Zitat Bonnefoy O, Ferretti G, Calaque O et al (2004) Serial chest CT findings in interstitial lung disease associated with polymyositis–dermatomyositis. Eur J Radiol 49:235–244PubMedCrossRef Bonnefoy O, Ferretti G, Calaque O et al (2004) Serial chest CT findings in interstitial lung disease associated with polymyositis–dermatomyositis. Eur J Radiol 49:235–244PubMedCrossRef
16.
Zurück zum Zitat Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 126:633–637PubMedCrossRef Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 126:633–637PubMedCrossRef
17.
Zurück zum Zitat Buising KL, Thursky KA, Black JF et al (2006) A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 61:419–424PubMedCrossRef Buising KL, Thursky KA, Black JF et al (2006) A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 61:419–424PubMedCrossRef
18.
Zurück zum Zitat Yamasaki Y, Yamada H, Nozaki T et al (2006) Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 54:2004–2009PubMedCrossRef Yamasaki Y, Yamada H, Nozaki T et al (2006) Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 54:2004–2009PubMedCrossRef
19.
Zurück zum Zitat Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV (1990) Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 141:727–733PubMed Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV (1990) Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 141:727–733PubMed
20.
Zurück zum Zitat Sakamoto N, Mukae H, Fujii T et al (2004) Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Internal Med 43:838–842CrossRef Sakamoto N, Mukae H, Fujii T et al (2004) Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Internal Med 43:838–842CrossRef
21.
Zurück zum Zitat Miyazaki E, Ando M, Muramatsu T et al (2005) Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 20:1–4 Miyazaki E, Ando M, Muramatsu T et al (2005) Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 20:1–4
22.
Zurück zum Zitat Caproni M, Cardinali C, Parodi A et al (2002) Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Arch Dermatol 138:23–27PubMedCrossRef Caproni M, Cardinali C, Parodi A et al (2002) Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Arch Dermatol 138:23–27PubMedCrossRef
23.
Zurück zum Zitat Fujisawa T, Suda T, Nakamura Y et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58–64PubMed Fujisawa T, Suda T, Nakamura Y et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58–64PubMed
24.
Zurück zum Zitat Fergusson RJ, Davison NM, Nuki G, Crompton GK (1983) Dermatomyositis and rapidly progressive fibrosing alveolitis. Thorax 38:71–72PubMedCrossRef Fergusson RJ, Davison NM, Nuki G, Crompton GK (1983) Dermatomyositis and rapidly progressive fibrosing alveolitis. Thorax 38:71–72PubMedCrossRef
25.
Zurück zum Zitat Nawata Y, Kurasawa K, Takabayashi K et al (1999) Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 26:1527–1533PubMed Nawata Y, Kurasawa K, Takabayashi K et al (1999) Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 26:1527–1533PubMed
26.
Zurück zum Zitat Hirakata M, Nagai S (2000) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501–508PubMedCrossRef Hirakata M, Nagai S (2000) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501–508PubMedCrossRef
27.
Zurück zum Zitat Yamasaki Y, Yamada H, Yamasaki M et al (2006) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46:124–130CrossRef Yamasaki Y, Yamada H, Yamasaki M et al (2006) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46:124–130CrossRef
28.
Zurück zum Zitat Swigris JJ, Olson AL, Fischer A et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130:30–36PubMedCrossRef Swigris JJ, Olson AL, Fischer A et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130:30–36PubMedCrossRef
29.
Zurück zum Zitat Tsukamoto H, Nagafuji K, Horiuchi T et al (2006) A phase I–II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 65:508–514PubMedCrossRef Tsukamoto H, Nagafuji K, Horiuchi T et al (2006) A phase I–II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 65:508–514PubMedCrossRef
30.
Zurück zum Zitat Blumenthal D, Hsiao W (2005) Privatization and its discontents—the evolving Chinese health care system. N Engl J Med 353:1165–1170PubMedCrossRef Blumenthal D, Hsiao W (2005) Privatization and its discontents—the evolving Chinese health care system. N Engl J Med 353:1165–1170PubMedCrossRef
31.
Zurück zum Zitat Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825–831PubMedCrossRef Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825–831PubMedCrossRef
32.
Zurück zum Zitat Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576PubMedCrossRef Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576PubMedCrossRef
Metadaten
Titel
Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study
verfasst von
Shuang Ye
Xiao-xiang Chen
Xiao-ye Lu
Mei-fang Wu
Yun Deng
Wen-qun Huang
Qiang Guo
Cheng-de Yang
Yue-ying Gu
Chun-de Bao
Shun-le Chen
Publikationsdatum
01.10.2007
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 10/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0562-9

Weitere Artikel der Ausgabe 10/2007

Clinical Rheumatology 10/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.